Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management
Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities. Background: Parkinson’s disease (PD) is a complex…Phantom boarder syndrome associated with experimentally-induced presence hallucinations in Parkinson’s disease
Objective: Measuring experimentally-induced presence hallucinations in patients with Parkinson’s disease phantom boarder phenomena. Background: Phantom boarder syndrome (PB) is described as the sensation that someone…Reduced Risk of Mortality and Antipsychotics in Parkinson’s Disease-Related Psychosis: Pimavanserin vs Off-Label Antipsychotics
Objective: Summarize the available data for the mortality risk associated with Parkinson’s disease (PD) psychosis (PDP) and pimavanserin. Background: PDP is associated with increased mortality…Parkinson’s Disease and Psychosocial Impact: Anxiety, Depression and Positive Symptoms
Objective: Explore the relationship between patient self-reported assessment of positive symptoms, depression, and anxiety in PwPD. Background: Parkinson’s disease (PD) is a complex neurodegenerative disorder…Risk of Long-term Care Admissions Among Medicare Patients Treated with Pimavanserin or Other Atypical Antipsychotics for Parkinson’s Disease Psychosis
Objective: To examine all-cause long-term care (LTC) admission risk among PDP patients treated with atypical antipsychotic (AAP). Background: Risk of LTC-admissions associated with off-label AAPs…Motor-Related and Cognition-Related Safety of Pimavanserin in Patients with Parkinson’s Disease Psychosis (PDP)
Objective: Evaluate motor- and cognition-related safety in pimavanserin-treated patients with PDP. Background: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only US FDA-approved treatment for…Psychosis in Parkinson’s disease and polymorphisms of the HOMER1 and COMT genes: Is there an association?
Objective: To investigate if polymorphisms of the HOMER1 and COMT gene are associated with psychosis in Parkinson’s disease (PD). Background: Psychosis is one of the…Alteration of lysosomal enzymatic activities in blood of patients with schizophrenia
Objective: To estimate whether alteration of lysosomal activities contributes to schizophrenia (SCZ) pathogenesis, age at onset and risk of developing the disease. Background: SCZ is…Antipsychotic use in Parkinson’s disease: a single center retrospective chart review
Objective: To assess the prevalence of antipsychotic (AP) use in people with Parkinson’s disease (PwP), and identify factors associated with AP prescription and differences in…Longitudinal study of clinical symptoms associated with psychosis in Parkinson’s disease without dementia
Objective: Examine clinical features associated with psychosis among Parkinson’s disease (PD) patients without dementia. Background: Previously identified risk factors for PD psychosis include duration and…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »